265 related articles for article (PubMed ID: 22014006)
1. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Eichbaum M; Mayer C; Eickhoff R; Bischofs E; Gebauer G; Fehm T; Lenz F; Fricke HC; Solomayer E; Fersis N; Schmidt M; Wallwiener M; Schneeweiss A; Sohn C
BMC Cancer; 2011 Oct; 11():453. PubMed ID: 22014006
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Sharma A; Singh M; Chauhan R; Malik PS; Khurana S; Mathur S; Kumar S; Sreenivas V; Kumar L
Gynecol Oncol; 2021 Aug; 162(2):382-388. PubMed ID: 34088513
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.
Gulia S; Ghosh J; Bajpai J; Rath S; Maheshwari A; Shylasree TS; Deodhar K; Thakur M; Gupta S
JCO Glob Oncol; 2020 Mar; 6():542-547. PubMed ID: 32228315
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
[TBL] [Abstract][Full Text] [Related]
6. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
[TBL] [Abstract][Full Text] [Related]
7. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
9. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Friedlander M; Hancock KC; Rischin D; Messing MJ; Stringer CA; Matthys GM; Ma B; Hodge JP; Lager JJ
Gynecol Oncol; 2010 Oct; 119(1):32-7. PubMed ID: 20584542
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Morgan RD; Banerjee S; Hall M; Clamp AR; Zhou C; Hasan J; Orbegoso C; Taylor S; Tugwood J; Lyon AR; Dive C; Rustin GJS; Jayson GC
Gynecol Oncol; 2020 Mar; 156(3):545-551. PubMed ID: 31932108
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH
Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E; Lynam S; Attwood KM; Wang C; Chilakapati S; Gomez EC; Liu S; Akers S; Lele S; Frederick PJ; Odunsi K
JAMA Oncol; 2021 Jan; 7(1):78-85. PubMed ID: 33211063
[TBL] [Abstract][Full Text] [Related]
16. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
Wong CN; Wong CN; Liu FS
Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Gupta R; Cristea M; Frankel P; Ruel C; Chen C; Wang Y; Morgan R; Leong L; Chow W; Koczywas M; Koehler S; Lim D; Luu T; Martel C; McNamara M; Somlo G; Twardowski P; Yen Y; Idorenyi A; Raechelle T; Carroll M; Chung V
Cancer Treat Res Commun; 2019; 21():100155. PubMed ID: 31279962
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Selle F; Sevin E; Ray-Coquard I; Mari V; Berton-Rigaud D; Favier L; Fabbro M; Lesoin A; Lortholary A; Pujade-Lauraine E
Ann Oncol; 2014 Nov; 25(11):2191-2196. PubMed ID: 25210017
[TBL] [Abstract][Full Text] [Related]
19. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
